Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...
Praxis shares slump as committee says drug trial unlikely to meet main goal
Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...
Hosted on MSN3d
Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (JAZZ)
Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...
Truist Financial Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed ...
Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) ...
Jazz downgraded to neutral by Cantor over business strategy
Cantor downgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to neutral from overweight, citing the company's increasing focus on ...
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
Strong Uptake of Xywav and Epidiolex Drive Growth for Jazz Pharmaceuticals
We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...
FiercePharma4d
Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
Jazz: Q4 Earnings Snapshot
Jazz expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $4.15 billion to $4.4 billion. This story was generated by Automated Insights ( ...